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Introduction
A major goal in our laboratories is the discovery of novel
compounds, which can alleviate the devastating effects of
liver cancers. The importance of such goals is axiomatic when
one considers, for example, that approximately 20% of can-
cer-related deaths in the United States are due to primary
liver tumors (arising from the hepatobiliary system) or sec-
ondary malignancies (tumors of extrahepatic origins, which
metastasize in the liver) [1]. The most common primary liver
cancers are hepatocellular carcinomas, which are often
referred to as hepatomas. Hence, the first step in our long-
term strategy is to find some prototypic molecules, which are
cytotoxic to a human hepatoma cell line.
The design of the cluster of molecules described in this
report, namely series 1 and 2, was based on the following
considerations.
(1) The compounds are structurally divergent from con-
temporary drugs used in treating hepatomas, such as 5-fluo-
rouracil [2] and doxorubicin [3]. Thus, series 1 and 2 may have
different modes of action than the drugs used today, and
hence be efficacious in treating drug-resistant tumors.
(2) Series 1 and 2 are acyclic Mannich bases and a number
of these compounds have demonstrated cytotoxic and anti-
cancer properties [4–9].
(3) Various cytotoxic Mannich bases exert their bioactivity,
at least in part, by interfering with respiration in mitochon-
dria [10, 11]. Recent surveys have emphasized a number of
biochemical differences betweenmitochondria isolated from
tumors and normal cells [12-14]. On occasion, greater toxicity
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to neoplasms than the corresponding non-malignant tissues
may result.
(4) Solutions of acyclic Mannich bases such as 1 and 2,
which possess a methine group (CH) adjacent to the carbonyl
substituent, may undergo deamination to the corresponding
a,b-unsaturated ketones [15, 16]. In general, these enones
react preferentially or exclusively with thiols rather than
amino or hydroxy groups [17, 18]. Since thiols are absent
in nucleic acids, a,b-unsaturated ketones may not cause the
genotoxic effects associated with a number of the anticancer
drugs used today [19].
(5) Cytotoxins should have a balance between hydrophilic
and hydrophobic groups, so that adequate quantities of the
compounds can reach the sites of action. Hydrophobic groups
were incorporated into series 1 and 2, such as the aryl and
heteroaryl rings as well as the isopropylamino group, which
should increase the rate and extent of absorption via mem-
branes. However, increasing the logP values of the molecules
reduces aqueous solubility, which in turn lowers the absorp-
tion of compounds from body compartments. Hence, the
hydrophilic amine hydrochloride group is present in 1 and 2.
(6) Various substituents were placed in the aryl ring of 1a–i,
which differ in the magnitude of their electronic, hydro-
phobic, and steric properties. This design was undertaken
with the goal of ascertaining whether cytotoxic potencies are
correlated with one or more of these physicochemical
parameters. Compound 2 was prepared in order to compare
its cytotoxicity with that of its bioisostere 1a.
(7) A secondary amino group is present in series 1 and 2 in
order to allow future molecular modifications at this portion
of the molecule to occur depending on the initial bioactivity
noted with 1a–i and 2. For example, N-acylation may be
deemed appropriate in attempts to improve pharmacody-
namic and/or pharmacokinetic properties.
(8) Finally 1a–i and 2 possess a number of druglike proper-
ties. Thus, the rules of Lipinski (molecular weight: <500,
logP < 5, hydrogen bond donors: <5, hydrogen bond accep-
tors: <10) [20] and Veber (rotatable bonds: <10, polar surface
area: <140 A˚2 or hydrogen bonds: <12) [21] are observed.
In summary, the aims of the present investigation were to
prepare series 1 and 2 and evaluate their cytotoxic potencies
towards a human hepatoma cell line, and secondly to under-
take analyses of the biodata with a view to establishing
guidelines for expansion of the project.
Results
The compounds in series 1 and 2 were prepared by the
synthetic chemical route outlined in Scheme 1. X-ray crys-
tallography was undertaken on 1d and 1g and ORTEP dia-
grams of these two compounds are presented in Figs. 1 and 2.
All of the compounds were evaluated against human hepa-
toma Huh-7 cells and the biodata generated is portrayed in
Table 1. Quantitative structure-activity relationship (QSAR)
and molecular modeling techniques were undertaken using
the biodata generated and various physicochemical proper-
ties of 1a–i and 2.
Discussion
The compounds in series 1 and 2 were prepared by the
Mannich reaction. The use of a primary amine means that
the initial Mannich base formed could react further with a
ketone and formaldehyde [22]. For example, in the case of the
attempted synthesis of series 1, the formation of the corre-
sponding N,N-bis(3-aryl-3-oxopropyl)isopropylamine hydro-
chlorides may have occurred. Furthermore, Mannich
reactions involving an aryl ethyl ketone, which contain a
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Scheme 1. The synthetic chemical route used to prepare the compounds in series 1 and 2.
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strongly electron-releasing group in the aryl ring such as a 4-
hydroxy substituent, may undergo ring aminomethylation
[23]. Hence, the products isolated were examined very care-
fully using multiple analytical techniques, namely 1H- and
13C-NMR as well as infrared spectroscopy, mass spectrometry,
and elemental analyses. In addition, X-ray crystallography of
two representative compounds 1d and 1g provided unequi-
vocal evidence that the Mannich bases prepared have the
structures presented in Scheme 1.
The IC50 values of 1a–i and 2 against human hepatoma
Huh-7 cells, which are presented in Table 1, reveal that the
objective of finding one or more compounds with growth-
inhibiting properties towards a liver cancer has been
achieved. In terms of structure-activity relationships (SAR),
the following observations were made. First, the potencies
of the compounds reveal three groups of molecules, namely
1a–c, g, i and 2 having IC50 values in the 15–20 mM range, 1h
possessing an IC50 figure of 65 mM and 1d–f displaying IC50
values in excess of 100 mM. Second, the six compounds with
the lowest IC50 figures are 2.1–2.8 times more potent than 5-
fluorouracil and even 1h has 0.7 times the potency of this
established drug. Thus, further development will be based on
the results obtained for 1a–c, g, i and 2. Third, the bioisosteres
1a and 2 have comparable potencies. Fourth, the insertion of
an ortho chloro substituent into 1d leading to 1i is accom-
panied by a 19-fold increase in potency.
The next phase of the investigation was aimed at detecting
correlations between the cytotoxic potencies of 1a–i and a
number of physicochemical parameters of the compounds.
The magnitude of the electronic, hydrophobic and steric
properties of the aryl substituents may be expressed by the
Hammett s/Taft s, Hansch p and molar refractivity (MR)
values, respectively, of these groups. Linear and semilogar-
ithmic plots were constructed between the IC50 values of 1a–i
and the s/s, p and MR figures of the aryl substituents. In
addition, logarithmic plots were made between the MR val-
ues and the IC50 data. However, no correlations (p > 0.05) or
trends to significance (p > 0.1) were found. If the principal
mode of action of 1a–i is the reaction of cellular thiols with
the a,b-unsaturated ketones liberated from 1a–i by deami-
nation, then the electrophilicity of the enones, which is
dependent on the s and s values of the aryl substituents,
should correlate negatively with the IC50 figures. This lack of
correlation noted in the statistical analyses suggests that
alternative mechanism(s) of action are primarily responsible
for the cytotoxic potencies.
The variation in cytotoxic potencies observed may have
been due to differences in the shapes of themolecules. Hence,
the decision was made to measure certain torsion angles,
interatomic distances and atomic charges, which might
govern the magnitude of the biological responses.
Molecular models of 1a–i and 2 were therefore built. The
numbers allocated to certain atoms of 1a–i are displayed in
Fig. 2, while Fig. 3 indicates the numbering of 2.
On occasions the size of the torsion angle between an aryl
ring and an adjacent unsaturated group is correlated with
biological potencies [24]. The torsion angles (u) C6-C1-C7-O in
1a–i and C2-C1-C6-O in 2 were determined and are presented
in Table 1. The u values of 1a–i may be influenced by the
electronic properties of the aryl substituents. For example,
electron-releasing groups may lower u figures by enhancing
the overlap of thep orbitals of the aryl ring with the adjacent
carbonyl group. A linear plot between the s/s values of the
aryl substituents in 1a–i and the u figures supported this view
since a positive trend towards significance (p ¼ 0.1) was
revealed. Since four of the five compounds in series 1, which
possess IC50 values in the 15–20 mM range, have s figures of
zero (1a) or are negative (1b, c, g), future studies should
include the insertion of one or multiple aryl substituents,
Figure 1. An ORTEP drawing of 1d. The displacement ellipsoids
are drawn at the 40% probability level.
Figure 2. An ORTEP drawing of 1g. The displacement ellipsoids
are drawn at the 40% probability level.
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Figure 3. The numbering of the atoms in 2 which are used in the
molecular modeling studies.
Arch. Pharm. Chem. Life Sci. 2011, 11, 333–339 Cytotoxic 1-aryl-3-isopropylamino-1-propanone hydrochlorides 335
 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.archpharm.com
which are strongly electron-releasing such as the dimethyla-
mino group (sp ¼ –0.83) [25]. A second observation of inter-
est is as follows. The u value of the 4-chloro analog 1d is
33.518. This figure was tripled when an ortho chloro atomwas
inserted into the molecule giving rise to 1i, which was
accompanied by a huge rise in potency. Thus, future modi-
fications should explore carefully the importance of placing
ortho substituents in the aryl ring in terms of potency vari-
ation. Third, the C2-C1-C6-O torsion angle in 2 is substantially
lower than the value found in 1a–i. The fact that 2 has
favorable cytotoxic properties suggests that replacement of
the 2-thienyl group by other heterocycles, which create differ-
ent u values, should be undertaken such as the formation of
the 2-pyrimidinyl or 6-methyl-2-pyridinyl analogs. Fourth, X-
ray crystallography of 1d and 1g was carried out, not only to
confirm the structures proposed for series 1, but also to
determine if the u values varied in compounds with aryl
substituents having markedly divergent sp values. The 4-
chloro analog 1d has two independent conformational iso-
mers in each asymmetric unit and the ufigures are 173.88 and
170.18. In the case of the 4-hydroxy Mannich base 1g, the u
value is –5.98. As noted with the molecular modeling deter-
minations, the u figure of 1d is slightly greater than 1g. The u
figures for 1d and 1g, which were generated using X-ray
crystallography, are lower than the values obtained by mol-
ecular modeling. This observation may be attributed to vari-
ations in the physical state of the molecules when the
determinations were made.
The compounds in series 1 and 2 are flexible molecules
permitting rotation about a number of single bonds, such as
the C7-C8 and C8-C9 bonds in series 1. Hence, the question
arises as to whether the shapes of the molecules differ in
terms of distances between these atoms in series 1 and 2,
which would be predicted to react at a binding site. The spans
between the carbonyl oxygen and the basic nitrogen atoms in
1a–i and 2 were measured and these data are presented in
Table 1. The results indicate that there is little variation in the
O-NH distances. In order to bring about changes in the O-NH
distances, various groups should be placed in carbon atoms 8
and 9 in 1a–i and 7 and 8 in 2, which may lead to significant
differences in the topography of the molecules including the
O-N distances, which could result in variations in potencies.
Finally, the atomic charges on the C8 atoms and the oxy-
gen atoms of the carbonyl groups in 1a–i, which are pre-
sented in Table 1 were determined for the following reasons.
The rate of elimination of isopropylamine hydrochloride
from 1a–i will be influenced by the lability of the protons
on the C8 methylene group, which in turn will be controlled
by the atomic charge on the C8 atoms. The data in Table 1
reveal that the atomic charges on the C8 atoms of 1a–i are
very similar and hence the difference in potencies among
these compounds is unlikely to be due to variations in the
rates of formation of the corresponding a,b-unsaturated
ketones. The size of the atomic charge on the carbonyl oxy-
gen atom is perceived to govern both the ability and extent of
the formation of hydrogen bonds at a receptor. Linear plots
between these charges and the s/s constants of the aryl
substituents of 1a–i revealed a positive correlation (p < 0.01).
Thus, electron-releasing groups in the aryl rings in series 1
increase the size of the negative change on this oxygen atom.
However linear, semilogarithmic and logarithmic plots
between the IC50 values of 1a–i and the atomic charge on
this oxygen atom did not reveal any relationship (p > 0.1).
Thus from this initial investigation, various guidelines for
analog development may be made. First, 1a–c, g, i and 2 are
lead molecules and the aryl substituents present in 1b, c, g, i
should be placed in different locations in the aryl ring. In
particular, since three of four of these compounds have
Table 1. Evaluation of 1a–i and 2 against Huh-7 cells and some physicochemical characteristics of these molecules
Compound IC50
a ub O-NHc Atomic charges (esu)
(mM) (8) (A˚) C8 O
1a 19 33.53 2.299 0.218 0.297
1b 18 32.31 2.304 0.218 0.299
1c 19 29.87 2.308 0.218 0.303
1d 286 33.51 2.303 0.218 0.293
1e 385 31.89 2.308 0.218 0.295
1f 225 34.83 2.301 0.217 0.290
1g 19 29.93 2.309 0.218 0.320
1h 65 40.46 2.330 0.208 0.280
1i 15 99.90 2.341 0.211 0.273
2 20 1.06 2.332 — —
5-Fluorouracil 42.2 — — — —
a The IC50 value is the average of two independent determinations.
b The u figures are the torsion angles between the C6-C1-C7-O atoms
in 1a–i and the C2-C1-C6-O atoms in the case of 2.c The O-NH distance is the span between the carbonyl oxygen atom and the nitrogen
atom attached to the isopropyl group in 1a–i and 2.
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electron-releasing aryl groups, priority should be given to
incorporating multiple methyl, methoxy and hydroxy
groups into the aryl rings such as the formation of the
3,4,5-trimethyl analog. Second, the influence of ortho sub-
stituents on IC50 figures needs to be developed in consider-
able detail. Third, changes in the conformation of the
molecule by inserting groups on the C8 and C9 atoms in
series 1 and C7 and C8 atoms in series 2 should be
undertaken.
Conclusions
A number of reasons for preparing series 1 and 2 as candidate
antineoplastics have been given and in particular the aspira-
tion of their ability to inhibit the growth of human hepatoma
cells. A series of prototypic molecules were prepared and
their structures thoroughly established. Not less than 60%
of the compounds evaluated have greater potency than 5-
fluorouracil against human Huh-7 hepatoma cells. By assess-
ing various physicochemical properties of these molecules,
guidelines for the design of further analogs were achieved.
Future investigations that should be undertaken include
mode of action studies, especially to evaluate whether the
compounds interfere with mitochondrial function, stability
studies of solutions of the compounds and whether greater
toxicity to neoplasms than normal cells is demonstrated.
Experimental
General
Melting points were determined using a Buchi 530 instrument
and are uncorrected. 1H-NMR (400 MHz) and 13C-NMR (100 MHz)
of 1a–i and 2 were determined on a Varian Mercury Plus
spectrometer. The electron-impact mass spectra were obtained
using a Thermo-Finnegan mass analyzer while the infrared
spectra were determined as potassium bromide discs on a
Mattson1000 FT-IR spectrophotometer. The elemental analyses
were generated using a Leco CHNS-932 instrument.
Synthesis of series 1 and 2
A mixture of the appropriate ketone (50 mmol), paraformalde-
hyde (50 mmol), and isopropylamine hydrochloride (27 mmol)
was heated in an oil bath at 1308C. The reaction vessel was then
removed from the oil bath and when the temperature of the
mixture dropped to 658C, ethyl acetate (40–80 mL) was added.
The mixture was stirred at room temperature for 24 h and the
resultant precipitates were then collected and, with the excep-
tion of 1f, were recrystallized from ether/methanol (1a, b, d, 2) or
methanol (1c, e, g–i). The Mannich base 1f was passed through a
column of silica gel 60 (70–230 mesh) using methanol as the
eluant and after evaporation of the solvent, the product was
recrystallized from methanol.
The 1H-NMR, 13C-NMR and IR spectroscopy as well as the mass
spectra and elemental analyses of 1a–d, h, which have been
described previously, are consistent with the proposed
structures. The melting points and yields of these compounds
are as follows, namely 1a: 172–1748C (lit. [26] m.p. 174–1768C),
55%; 1b: 170–1718C (lit. [27] m.p. 171–1728C), 58%; 1c: 176–1788C
(lit. [28] 1838C), 64%; 1d: 168–1708C (lit. [27] m.p. 167–1688C, 52%;
1h: 206–2078C (lit. [28] m.p. 207–2088C), 20%.
1-(4-Fluorophenyl)-3-isopropylamino-1-propanone
hydrochloride 1e
M.p. 189–1908C. Yield: 44%. 1H-NMR (CDCl3) d 1.51 (d, J ¼ 6.8 Hz,
6H, CH(CH3)2), 3.36–3.40 (m, 3H, CH(CH3)2 and 2  H-2), 3.75 (t,
J ¼ 7.1 Hz, 2H, 2  H-3), 7.04–7.08 (m, 2H, H-3’/5’), 7.94–7.96 (m,
2H, H-2’/6’), 9.55 (brs, 2H, NH2
þ); 13C-NMR (CDCl3) d 19.4
(CH(CH3)2), 35.1, 40.3, 51.3, 116.2, 131.1, 132.5, 166.4, 195.5
(CO); MS (EI) m/z: 194.1 (M – CH3)
þ, 209.1 (M)þ; IR (KBr, cm1):
2446 (NH2
þ), 1681 (CO). Calcd. for C12H17ClFNO (245.72): C, 58.66;
H, 6.97; N, 5.70. Found: C, 58.51; H, 6.94; N, 5.74.
1-(4-Bromophenyl)-3-isopropylamino-1-propanone
hydrochloride 1f
M.p. 174–1768C. Yield: 38%. 1H-NMR (CDCl3) d 1.49 (d, J ¼ 6.8 Hz,
6H, CH(CH3)2), 3.34–3.38 (m, 3H, CH(CH3)2 and 2  H-2), 3.73 (t,
J ¼ 7.3 Hz, 2H, 2  H-3), 7.50 (d, J ¼ 8.4 Hz, 2H, H-3’/5’), 7.76 (d,
2H, J ¼ 8.4 Hz, H-2’/6’), 9.55 (brs, 2H, NH2þ); 13C-NMR (CDCl3) d
19.4 (CH(CH3)2), 35.3, 40.2, 51.3, 129.4, 129.8, 132.3, 134.7, 195.8
(CO); MS (EI) m/z: 254 (M – CH3)
þ, 256 (M – CH3 þ 2)þ, 270.2
(M þ H)þ, 272.2 (M þ H þ 2)þ; IR (KBr, cm1): 2462 (NH2þ), 1684
(CO). Calcd. for C12H17BrClNO (306.63): C, 47.00; H, 5.59; N, 4.57.
Found: C, 46.74; H, 5.52; N, 4.59.
1-(4-Hydroxyphenyl)-1-isopropylamino-1-propanone
hydrochloride 1g
M.p 195–1968C. Yield: 10%. 1H-NMR (CD3OD) d 1.39 (d, J ¼ 6.4 Hz,
6H, CH(CH3)2), 3.37–3.46 (m, 5H, CH(CH3)2, 2  H-2 and 2  H-3),
4.87 (brs, 1H, OH), 6.87 (d, J ¼ 8.8 Hz, 2H, H-3’/5’), 7.92 (d,
J ¼ 8.8 Hz, 2H, H-2’/6’); 13C-NMR (CD3OD) d 18.0 (CH(CH3)2),
34.0, 40.2, 51.2, 115.3, 128.0, 130.7, 163.2, 195.6 (CO); MS (EI)
m/z: 192.4 (M – CH3)
þ, 206.3 (M – H)þ; IR (KBr, cm1): 2449 (NH2
þ),
1658 (CO). Calcd. for C12H18ClNO2 (243.73): C, 59.13; H, 7.44, N,
5.75. Found: C, 58.97; H, 7.62; N, 5.76.
3-(2,4-Dichlorophenyl)-1-isopropylamino-1-propanone
hydrochloride 1i
M.p. 158–1598C. Yield: 37%. 1H-NMR (CDCl3) d 1.47 (d, J ¼ 6.8 Hz,
6H, CH(CH3)2), 3.34–3.39 (m, 3H, CH(CH3)2 and 2  H-2), 3.73 (t,
J ¼ 7.1 Hz, 2H, 2  H-3), 7.24–7.26 (m, 1H, H-5’), 7.37 (s, 1H, H-3’),
7.64 (d, J ¼ 8.4 Hz, 1H, H-6’), 9.52 (brs 2H, NH2þ); 13C-NMR (CDCl3)
d 19.4 (CH(CH3)2), 39.1, 39.8, 51.4, 127.7, 130.9, 131.4, 132.7,
135.6, 138.6, 197.6 (CO); MS (EI) m/z: 244.1(M – CH3)
þ, 246.1(M
– CH3 þ 2)þ, 248(M – CH3 þ 4)þ, 259.1 (M)þ; IR (KBr, cm1): 2451
(NH2
þ), 1682 (CO). Calcd. for C12H16Cl3NO (296.62): C, 48.59; H,
5.44; N, 4.72. Found: C, 48.50; H, 5.36; N, 4.77.
3-Isopropylamino-1-(2-thienyl)-1-propanone hydrochloride 2
M.p. 165–1668C. Yield: 25%. 1H-NMR (CDCl3) d 1.51 (d, J ¼ 6.4 Hz,
6H, CH(CH3)2), 3.37–3.41 (m, 3H, CH(CH3)2 and 2  H-2), 3.73 (t,
J ¼ 7.3 Hz, 2H, 2  H-3), 7.05 (t, J ¼ 4.4 Hz, 1H, H-4’), 7.63 (d,
J ¼ 4.8 Hz, 1H, H-3’), 7.78 (d, J ¼ 3.6 Hz, 1H, H-5’), 9.56 (brs, 2H,
NH2
þ); 13C-NMR d 19.4 (CH(CH3)2), 35.6, 40.2, 51.2, 128.6, 133.4,
134.9, 142.9, 189.7 (CO); MS (EI) m/z: 182.1 (M – CH3)
þ, 197.0 (M)þ;
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IR (KBr, cm1): 2460 (NH2
þ), 1659 (CO). Calcd. for C10H16ClNOS
(233.76): C, 51.38; H, 6.90: N, 5.99; S, 13.72. Found: C, 51.37; H,
6.96; N, 6.09; S, 13.92.
Statistical analyses
The s, p, and MR values were culled from an appropriate
reference [29], while the s figure was obtained from the
literature [30]. The linear, semilogarithmic and logarithmic plots
as well as the multilinear regression analyses were made using a
commercial software package [31].
Molecular modeling
Models of the compounds 1a–i and 2 were built using a Spartan
software [32]. The structures were reoptimized using semi-
empirical quantum mechanical calculations by the AM1
method.
X-Ray Crystallography
For the crystal structure determination, the single-crystals of the
compounds 1d and 1g were used for data collection on a four-
circle Rigaku R-AXIS RAPID-S diffractometer (equipped with a
two-dimensional area IP detector). The graphite-monochromat-
ized Mo Ka radiation (l ¼ 0.71073 A˚) and oscillation scans tech-
nique with Dv ¼ 58 for one image were used for data collection.
The lattice parameters were determined by the least-squares
methods on the basis of all reflections with F2 > 2 s (F2).
Integration of the intensities, correction for Lorentz and polar-
ization effects and cell refinement was performed using
CrystalClear [33] The structures were solved by direct methods
using SHELXS-97 [34] and refined by a full-matrix least-squares
procedure using the program SHELXL-97 [34]. The final difference
Fourier maps showed no peaks of chemical significance.
Crystal data for 1d: C12H17Cl2NO, crystal system, space group:
orthorhombic, P212121; (no:2); unit cell dimensions: a ¼ 7.2652
(2) A˚, b ¼ 12.9951 (3) A˚, c ¼ 29.2708 (4) A˚, a ¼ 908, b ¼ 908,
g ¼ 908; volume: 2763.4(2) A˚3; Z ¼ 8; calculated density:
1.26 mg/m3; absorption coefficient: 0.451 mm1; F(000): 1104;
u range for data collection 2.6–26.58; refinement method: full-
matrix least-square on F2; data/parameters: 2557/293; goodness-
of-fit on F2: 1.019; final R indices [I > 2 s(I)]: R1 ¼ 0.071,
w R2 ¼ 0.149; R indices (all data): R1 ¼ 0.161, w R2 ¼ 0.190; larg-
est diff. peak and hole: 0.222 and –0.185 e A˚3.
Crystal data for 1g: C12H18ClNO2, crystal system, space group:
triclinic, P-1; (no:2); unit cell dimensions: a ¼ 7.7720(2) A˚,
b ¼ 8.7180(3) A˚, c ¼ 10.3490(4) A˚, a ¼ 76.70(2)8, b ¼ 72.33(3)8,
g ¼ 86.27(2)8; volume: 650.2(2) A˚3; Z ¼ 2; calculated density:
1.24 mg/m3; absorption coefficient: 0.280 mm1; F(000): 260; u
range for data collection 2.1–26.48; refinement method: full-
matrix least-square on F2; data/parameters: 2661/156; good-
ness-of-fit on F2: 1.012; final R indices [I > 2 s(I)]: R1 ¼ 0.056,
w R2 ¼ 0.126; R indices (all data): R1 ¼ 0.091, w R2 ¼ 0.147; larg-
est diff. peak and hole: 0.173 and –0.214 e A˚3.
In the structure 1d, hydrochlorides are joined by N-HCl H-
bonds [N’Cl(2) ¼ 3.117(7) A˚, N’-H(2B)Cl(2) ¼ 1708;
NCl(2’) ¼ 3.139(7) A˚, N-H(1A)Cl(2’) ¼ 1698]. The compound
1g crystallizes in the triclinic space group P-1, with two mol-
ecules in the unit cell. In this structure, hydrochlorides are
joined by N-HCl and O-HCl H bonds [NCl ¼ 3.196(3) A˚, N-
HCl ¼ 1778; NCla ¼ 3.199(3) A˚, N-H(1B)Cla ¼ 1668;
O(2)Clb ¼ 3.063(3) A˚, O(2)-H(2A)Clb ¼ 1718, symmetry code
(a); 1-x,-y,1-z (b); 1-x, 1-y,-z], which lead to the formation of double
polymeric chain. Crystallographic data for the structures 1d and
1g have been deposited with the Cambridge Crystallographic
Data Centre as supplementary publication no. CCDC-767024
and 752376, respectively. These data can be obtained free of
charge from the Cambridge Crystallographic Data Centre
(www.ccdc.cam.ac.uk/data_request/cif).
Cytotoxic evaluation of 1a-i and 2 on Huh-7 cells
The Mannich bases 1a–i and 2 were evaluated against Huh-7 cells
by a reported procedure [35]. The IC50 values, which were
obtained by a literature method [35] are the average of two
independent determinations which differed by less than 10%.
This study was supported by the Research Foundation of Ataturk University,
Erzurum, Turkey. Cytotoxicity experiments were perfomed at the KANIL TEK
anticancer biomolecule screening facility, Bilkent University.
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